NCT02291614View on ClinicalTrials.gov

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

November 27, 2014

Primary Completion Date

November 6, 2017

Study Completion Date

January 9, 2018

Conditions

GI Adenocarcinoma

Interventions

DRUG

AMG 211

continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Trial Locations (5)

20246

Research Site, Hamburg

81377

Research Site, München

89081

Research Site, Ulm

1081 HV

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

MedImmune LLC

INDUSTRY

lead

Amgen

INDUSTRY